Bone Biologics Reports Third-Quarter 2026 Net Loss of $618,000
Bone Biologics reported a net loss of $618,000 and diluted loss per share of $0.17 for the third quarter of 2026, compared with a $667,000 loss a year earlier.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.